Purple Biotech Ltd. establishes a Scientific Advisory Board with renowned experts in T-cell and NK cell therapies to guide development of its CAPTN-3 tri-specific antibody platform toward clinical stage.
Key takeaways
Purple Biotech forms SAB with experts in T-cell engagers, NK cell biology, and tumor immunology to support CAPTN-3 platform.
SAB members include Amir Horowitz PhD (NK cell expert, Mount Sinai), Afshin Dowlati MD (T-cell engagers in solid tumors, Case Western), Alexander Shoushtari MD (tebentafusp development, MSKCC), Max S. Topp MD (blinatumomab development, Würzburg).
CAPTN-3 features masked tri-specific antibodies targeting tumor antigens, engaging T and NK cells with tumor-specific activation to expand therapeutic window.
Lead CAPTN-3 candidates IM1240 (5T4-targeted) and IM1305 (TROP2-targeted) are in preclinical development advancing toward clinic.
CEO Gil Efron states SAB provides strategic guidance leveraging direct experience in approved T-cell engager therapies.